marked.bio

c-MET ADC · ADC

telisotuzumab adizutecan

3 active trials across 2 of our biomarkers, targeting c-MET. Not approved for any biomarker on marked.bio yet.

Also known as ABBV-400.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 19 deletion / L858R 2 2 Phase 2/3
BRAF V600E 1 1 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of telisotuzumab adizutecan.

  1. AbbVie 3

Trials

3 of 3 trials shown

  1. A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

    Recruiting Phase 2/3 AbbVie Started 2025Primary completion 2036-11 NCT07005102

    telisotuzumab adizutecanosimertinib FDA EUcisplatincarboplatinpemetrexed

    …d metastatic/locally advanced non-squamous NSCLC with documented classical EGFR mutation (Exon 19 Del or Exon 21 L858R) either alone or in combination with other EGFR mutations as detected by…

    EGFR exon 19 deletion / L858RNon-Squamous Non-Small Cell Lung Cancer, c-MET

  2. A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

    Recruiting Phase 2/3 AbbVie Started 2025Primary completion 2030-09 NCT07155187

    telisotuzumab adizutecanosimertinib FDA EU

    …vanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with documented EGFR Exon 19 deletion or Exon21 L858R mutation.

    EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer, c-MET

  3. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    Recruiting Phase 1 AbbVie Started 2021Primary completion 2027-07 NCT05005403

    Azirkitugbudigalimabbevacizumabtelisotuzumab adizutecan

    …essed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, BRAFV600E or HER2, other targetable mutations targeted with locally approved therapy, TAS-102, Rego…

    BRAF V600ENon-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer